Recent Posts on This Topic | See All >
Breast cancer drug Abraxane promising for malignant melanoma treatmentTags: arizona cancer center, cancer, melanoma, university of arizona
An approved breast-cancer drug nab-paclitaxel, trade named Abraxane, has been found promising in clinical trial for the treatment of metastatic malignant melanoma, revealed by researchers.
Researchers at the Arizona Cancer Center has used this drug for last 7 years, and resulted in the opening of a Phase 3 clinical trial.
For more information: Breast cancer drug Abraxane promising for malignant melanoma treatment
Now available: “Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes,” is now available along with its supplement, “Summary of Goals, Strategies, and Potential Actions.” An overview by Walter Plosila, Ph.D., Battelle senior advisor, is also available. The updated Roadmap provides a long-term strategy for Arizona to achieve bioscience success over the next decade.